A single protein — filaggrin — is responsible for assembling the skin's outermost waterproof layer and generating the natural moisturizing factor (NMF)¹¹ natural moisturizing factor (NMF)
a hygroscopic mixture of amino acids, urocanic acid, pyrrolidone carboxylic acid, urea, and ions that keeps the stratum corneum hydrated and maintains the acidic skin pH (4.5–5.5) essential for barrier function that protects against allergen penetration, infection, and water loss. The FLG gene encodes a massive precursor — profilaggrin — which is proteolytically cleaved during terminal epidermal differentiation into 10–12 filaggrin monomers. The 3702delG variant (c.3702delG) deletes a single guanine nucleotide in the coding sequence at position 3702, shifting the reading frame and generating a premature stop codon within filaggrin repeat domain 3. This eliminates all downstream filaggrin sequence from that allele — making 3702delG a complete null allele²² complete null allele
any FLG loss-of-function mutation that abolishes filaggrin protein production from the affected chromosome regardless of the mechanism (nonsense, frameshift, or splice site).

3702delG is the third most common FLG null allele in European populations, identified in Irish and Scottish ichthyosis vulgaris families alongside the previously characterized R501X (rs61816761) and 2282del4 (rs558269137). Notably, R501X and 2282del4 both affect repeat domain 1, while 3702delG affects domain 3 — yet the downstream clinical consequence is identical: loss of all filaggrin protein from that allele.

The Mechanism

Loss of one functional FLG allele (heterozygous 3702delG) reduces total filaggrin output by approximately 50%, impairing stratum corneum assembly and NMF production. Reduced NMF means higher transepidermal water loss (TEWL)³³ transepidermal water loss (TEWL)
a measure of how much water evaporates through the skin; elevated TEWL is a reliable marker of barrier deficiency even in carriers without clinical eczema, elevated skin pH, and structural gaps between corneocytes. These gaps allow environmental allergens — house dust mite, pollen, food proteins — to reach the viable epidermis and trigger IgE-mediated sensitization through the skin, before dietary exposure to those allergens has occurred. This percutaneous sensitization⁴⁴ percutaneous sensitization
allergen sensitization through the skin rather than the gut or lungs — the primary mechanism linking FLG null carrier status to food allergy and asthma is the molecular foundation of the atopic march.

Inheritance is semidominant: heterozygotes (DI) have an intermediate phenotype, commonly identifiable only by palmar hyperlinearity and mild dryness. When a carrier of 3702delG also carries a second FLG null allele — R501X or 2282del4 — on the other chromosome, the compound heterozygous state is equivalent to complete filaggrin absence: the severe phenotype of ichthyosis vulgaris homozygosity is expressed with high penetrance.

The Evidence

3702delG was first identified by Sandilands et al. 2006⁵⁵ Sandilands et al. 2006
Sandilands A et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol. 2006 in Irish families with ichthyosis vulgaris. A proband compound heterozygous for R501X/3702delG showed a severe phenotype clinically indistinguishable from R501X homozygosity, establishing that centrally positioned null mutations in the filaggrin repeat array are fully pathogenic. The broader comprehensive filaggrin gene analysis⁶⁶ comprehensive filaggrin gene analysis
Sandilands A et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007 characterized 3702delG as one of six prevalent European FLG null alleles, with an Irish case-control study demonstrating heterozygote odds ratio of 7.44 (95% CI not specified) for childhood eczema across the five most common European mutations combined.

The 3702delG allele is essentially absent outside Northwest European populations: it was not detected in control populations from Western Siberia, Spain, or East Asian cohorts, in contrast to R501X and 2282del4, which are found at lower but non-negligible frequencies in several populations globally. This geographic restriction reflects the Northwest European ancestry of the founding haplotype on which 3702delG arose.

The clinical framework established for R501X and 2282del4 applies equally to 3702delG, because the functional outcome is identical: FLG null alleles as a group confer OR 3.12 (95% CI 2.57–3.79) for atopic eczema⁷⁷ FLG null alleles as a group confer OR 3.12 (95% CI 2.57–3.79) for atopic eczema
Rodríguez et al. 2009: meta-analysis of 24 studies confirming eczema and asthma risk across FLG null mutations and OR 3.29 (95% CI 2.84–3.82) for eczema-associated asthma. Importantly, asthma risk disappears when eczema is absent, confirming that the skin barrier defect — not a direct airway effect — is the primary driver. Carriers of any two FLG null alleles (homozygous or compound heterozygous) carry odds ratio exceeding 10 for eczema herpeticum⁸⁸ eczema herpeticum
severe disseminated herpes simplex virus infection of eczematous skin — a medical emergency relative to eczema patients without FLG mutations.

A randomized controlled trial⁹⁹ randomized controlled trial
Simpson et al. 2014 JACI: daily emollient from birth reduced cumulative AD incidence by ~50% in high-risk infants over 6 months demonstrated that consistent barrier augmentation from birth reduces eczema incidence by approximately 50% in high-risk infants, establishing a clear intervention window for families with FLG null allele carriers.

Practical Actions

The barrier-support strategy for 3702delG carriers is identical to that for R501X and 2282del4 carriers — because the mechanism and deficit are the same. Ceramide-dominant emollients containing the physiologic 3:1:1 ratio of ceramides to cholesterol to free fatty acids replicate what a functional stratum corneum would produce. Urea-containing formulations (5–10% urea) are particularly beneficial because urea is both an NMF component and can upregulate residual FLG expression in skin cells. Fragrance, methylisothiazolinone (MI/MCI), sodium lauryl sulfate, and propylene glycol in personal care products disproportionately disrupt compromised barriers and should be eliminated.

Heterozygous carriers without current eczema should focus on proactive barrier maintenance during physiological stress periods — low humidity, cold weather, frequent handwashing, or prolonged water exposure — rather than waiting for symptoms. For parents carrying 3702delG: daily emollient from birth in high-risk infants is supported by RCT evidence, and early oral introduction of allergenic foods (peanut, egg, fish) — following current LEAP-trial-derived guidelines — is particularly critical in FLG-carrier families to prevent percutaneous sensitization from establishing food allergy before oral tolerance can develop.

Interactions

3702delG (rs397507563) is the third major European FLG null allele, and its most clinically significant interaction is compound heterozygosity with either R501X (rs61816761) or 2282del4 (rs558269137). When 3702delG is carried on one chromosome and either of these alleles on the other, the individual has no functional FLG gene — functionally equivalent to FLG null homozygosity. The R501X/3702delG compound heterozygous phenotype was clinically confirmed as indistinguishable from R501X homozygosity in the original characterization study. The management is identical to homozygosity: intensive twice-daily emollient therapy, dermatology referral, dupilumab consideration for moderate-to-severe eczema, and eczema herpeticum vigilance.

Proposed compound actions for supervisor: (1) When a user carries rs397507563 DI or DD AND rs61816761 AG or AA (3702delG + R501X compound heterozygous or R501X homozygous + 3702delG): complete FLG null state — intensive twice-daily ceramide-dominant emollient, dermatology referral, dupilumab evaluation, eczema herpeticum emergency recognition, early allergen introduction in offspring, barrier-disrupting ingredient elimination. Evidence level: established. (2) When a user carries rs397507563 DI or DD AND rs558269137 DI or DD (3702delG + 2282del4 compound heterozygous): complete FLG null state — identical management as above. Evidence level: established.

Your immune system deploys natural killer (NK) cells¹¹ natural killer (NK) cells
Innate immune lymphocytes that patrol for antibody-coated targets and kill them directly without prior sensitization as front-line defenders. On the surface of NK cells sits a receptor called FcgammaRIIIa (CD16a), encoded by the FCGR3A gene. This receptor grabs the tail end (Fc region) of IgG antibodies already bound to target cells — triggering antibody-dependent cellular cytotoxicity (ADCC)²² antibody-dependent cellular cytotoxicity (ADCC)
The killing process by which NK cells destroy antibody-flagged targets, including infected cells and cancer cells. The rs403016 variant introduces a rare missense change, replacing arginine with serine at position 36 of the mature CD16a protein. This Arg36Ser substitution sits in the extracellular immunoglobulin-like domain and may alter the receptor's structure or IgG binding characteristics. Chinese family-based genetic studies identified this variant as a susceptibility factor for systemic lupus erythematosus (SLE), though it is distinct from — and much rarer than — the well-characterized V158F polymorphism (rs396991)³³ V158F polymorphism (rs396991)
The established FCGR3A variant affecting IgG binding affinity and monoclonal antibody therapy response, present in ~30% of alleles globally in the same gene.

The Mechanism

FCGR3A is located on chromosome 1q23, a region that harbors multiple Fc gamma receptor genes (FCGR2A, FCGR2B, FCGR3A, FCGR3B) in close proximity. This region is a well-established susceptibility locus for SLE⁴⁴ susceptibility locus for SLE
Multiple independent variants in the 1q23 Fc receptor cluster have been linked to autoimmune disease through GWAS and family-based studies.

The rs403016 variant changes codon 36 from CGG (Arg) to AGC (Ser) in the canonical FCGR3A transcript (NM_000569.8). Arginine carries a positive charge while serine is uncharged and polar. This change at position 36 in the first extracellular immunoglobulin-like domain may disrupt a salt bridge or charge interaction that contributes to receptor folding or the IgG-binding interface. The downstream consequence — if the variant affects IgG binding — would be altered ADCC efficiency, potentially weakening clearance of immune complexes. In SLE, defective immune complex clearance allows IgG-coated nuclear fragments to accumulate, driving the autoantibody cascade and tissue inflammation.

NK cells in active SLE patients already show decreased CD16a surface expression compared to healthy controls⁵⁵ decreased CD16a surface expression compared to healthy controls
Hervier et al. 2011 found significantly reduced FcgammaRIIIa/CD16a expression on CD56dim NK cells in patients with active SLE, suggesting that reduced receptor function is a feature of active lupus. Whether rs403016 contributes to this phenotype by altering receptor stability or expression has not been directly tested.

The Evidence

Three Chinese family-based studies specifically examined rs403016. The original report by Ye et al. (2006)⁶⁶ Ye et al. (2006)
95 nuclear SLE families, 435 total subjects; family-based association using TDT and genotype relative risk analysis identified this as a novel FCGR3A SNP associated with SLE susceptibility in Chinese populations, with the R allele showing preferential transmission to affected offspring⁷⁷ the R allele showing preferential transmission to affected offspring
TDT chi-square = 9.30, P = 0.0032; additive model Z = 2.5444, P = 0.011.

A confirmatory study by Pan et al. (2007)⁸⁸ Pan et al. (2007)
119 SLE patients from 95 nuclear families plus 316 family members; additive and recessive genetic models tested replicated the association with SLE in the same population, finding significant results under both additive (P = 0.011) and recessive (P = 0.028) models. A subsequent haplotype analysis Pan et al. (2008)⁹⁹ Pan et al. (2008)
Examined haplotype structure across FCGR2B and FCGR3A; found no significant inter-gene haplotypes, suggesting FCGR3A-72 and FCGR2B variants act independently further confirmed single-marker association of rs403016 with SLE susceptibility.

Importantly, this evidence is limited to small Chinese family cohorts, with no independent replication in European, African, or other East Asian populations. The G allele is exceedingly rare globally — approximately 0.14% in Japanese populations (the highest documented frequency) and nearly absent in European and African populations (gnomAD v4). This extreme rarity means most large SLE GWAS studies, which are powered for common variants, would not detect it. The evidence level is therefore emerging — the association is statistically significant in the studied population but lacks broad replication.

Note: A marked discrepancy exists between the allele frequencies in the 2006-2008 Chinese studies (~39% "R allele") and current gnomAD data (<0.14% G allele globally). This may reflect changes in rs number assignment between genome builds, differences in how alleles were coded in early studies, or population-specific variation not captured by current databases. The plus-strand orientation used here (C = reference = Arg = common; G = alternate = Ser = rare risk allele) is consistent with current dbSNP annotation.

Practical Implications

Carrying the G allele at rs403016 is rare outside East Asian populations. In the context of SLE susceptibility, the G allele was associated with excess transmission to affected offspring in Chinese families — a statistically significant finding. However, SLE is a complex disease with many genetic and environmental contributors; no single rare variant is deterministic. The primary actionable implication for G allele carriers is heightened awareness of SLE warning signs and appropriate monitoring.

For individuals with this variant who are already monitored for autoimmune conditions (or who have family members with SLE), this variant adds to the overall genetic context. The FCGR3A gene is also relevant to NK cell-mediated immunity, so carriers might benefit from attention to immune health more broadly.

Interactions

The Fc gamma receptor cluster on chromosome 1q23 contains multiple interacting variants. rs403016 in FCGR3A may act in concert with the FCGR2A H131R variant (rs1801274), which affects IgG2 binding and is independently associated with SLE. The 2008 Pan et al. haplotype study found no significant cross-gene haplotype combining FCGR2B and FCGR3A variants in SLE susceptibility in their Chinese cohort, suggesting these loci act independently.

The more extensively studied FCGR3A V158F polymorphism (rs396991) — which affects IgG1 and IgG3 binding affinity and is present in ~30% of alleles globally — operates through a distinct mechanism at a different position in the same protein. These two FCGR3A variants could theoretically compound in a trans configuration, but no direct compound analysis has been published. The broader implication is that individuals with rs403016-G carrying additional Fc receptor risk alleles may have enhanced autoimmune susceptibility, though this remains hypothetical without direct study.

The major histocompatibility complex (MHC) on chromosome 6 is the most gene-dense immune region in the human genome, and its class III segment — wedged between the complement genes and the classical HLA loci — contains a cluster of RNA surveillance genes that few people know about. One of them, SKIV2L (Superkiller Viralicidic Activity 2-Like), encodes the RNA helicase at the heart of the cytoplasmic RNA exosome. rs419788 is an intronic variant within SKIV2L that marks an independent genetic susceptibility signal for systemic lupus erythematosus¹¹ independent genetic susceptibility signal for systemic lupus erythematosus
Fernando et al. 2007: family-based study of 314 UK SLE trios; rs419788-T allele OR 2.0, p=4.3×10⁻⁸; independent of HLA-DRB1*0301 by conditional analysis (SLE) — one that is completely separate from the HLA-DRB1 risk alleles that most people associate with lupus genetics.

The Mechanism

SKIV2L is the engine of the SKI complex, an evolutionarily ancient RNA surveillance machine. Its job is to unwind damaged, misfolded, and viral RNA substrates and feed them into the cytoplasmic RNA exosome for 3'→5' degradation. In the context of innate immunity, this has a crucial regulatory function: when the OAS-RNase L pathway detects viral double-stranded RNA, RNase L cleaves cellular and viral RNA into short fragments that can then re-trigger RIG-I-like receptor (RLR) signaling — amplifying the interferon response. SKIV2L acts as a brake on this amplification loop: it degrades RNase L-processed RNA fragments²² degrades RNase L-processed RNA fragments
Yang et al. 2024 EMBO J: SKIV2L-deficient cells show markedly elevated IFN responses to RNase L-processed RNA; helicase activity is required; SKIV2L loss exacerbates autoinflammation from OAS1 gain-of-function mutations before they can drive further interferon production.

A second, more recently described function connects SKIV2L directly to the B cell arm of autoimmunity. Conditional knockout of Skiv2l in B cell precursors³³ Conditional knockout of Skiv2l in B cell precursors
Science Immunology 2022; Skiv2l-deficient pro-B cells show cell cycle arrest, DNA damage, and failed V(D)J rearrangement of immunoglobulin heavy chain; mice lack both conventional B-2 and innate-like B-1 B cells causes a complete block at the pro-B to pre-B transition. Without SKIV2L-mediated RNA surveillance, pro-B cells accumulate aberrant RNA species that trigger DNA damage signaling and arrest development — the same pro-B stage where autoreactive B cell clones are normally selected against. Disrupted RNA quality control at this checkpoint may allow autoreactive precursors to escape normal negative selection.

rs419788 lies in intron 6 of SKIV2L. It does not change the protein sequence but likely affects regulatory elements or splicing efficiency, potentially altering SKIV2L expression in immune cell subsets. The exact functional consequence of the T allele on SKIV2L transcription or protein levels has not been published, but the association data are consistent with reduced or dysregulated SKIV2L activity weakening the brake on RLR signaling and B cell RNA surveillance.

The Evidence

The primary association was established by Fernando et al. in 2007⁴⁴ Fernando et al. in 2007
PLoS Genetics; 314 complete UK Caucasian SLE trios; TDT-based family analysis; rs419788-T OR 2.0 (95% CI 1.6–2.6), nominal p=4.3×10⁻⁸, permuted p<0.0001; two independent MHC signals (DRB1*0301 and rs419788-T) confirmed by conditional analysis in a family-based study of 314 UK SLE trios. The analysis used transmission disequilibrium testing — a design that is robust to population stratification, a serious confounder in MHC studies — and demonstrated that the SKIV2L class III signal and the HLA-DRB1*0301 class II signal are genetically independent: only 47% of rs419788-T haplotypes carry DRB1*0301. This means the two alleles act additively; carriers of both face the highest combined MHC risk.

A subsequent high-density MHC screen⁵⁵ high-density MHC screen
Barcellos et al. 2009 PLoS Genetics; 1,610 SLE cases and 1,470 controls; 1,974 MHC SNPs plus HLA-DRB1; SKIV2L SNPs including rs419788 showed p<0.01 in single-marker analysis but did not survive conditional haplotype method at p<0.01 threshold in 1,610 SLE cases confirmed that the SKIV2L locus harbours association signal, but rs419788 specifically did not survive the more stringent conditional analysis at that study's threshold. This pattern is consistent with rs419788 being a tagging SNP in moderate LD with a broader class III susceptibility haplotype spanning SKIV2L, STK19, and CFB, rather than the causal variant itself. The evidence level is therefore rated moderate: the association is well-replicated at the regional level, but the index SNP signal requires further fine-mapping to determine the causal variant.

SKIV2L sits between complement factor B (CFB) and STK19 — both of which also carry SLE associations. Disentangling the contribution of SKIV2L variants from complement pathway variants in this region remains an active area of research.

Practical Actions

For CT heterozygotes and TT homozygotes, the actionable implications center on SLE surveillance. The T allele marks elevated risk for an autoimmune disease defined by loss of self-tolerance, immune complex deposition, and organ damage — kidney, brain, and skin being the most common targets. Familial history of lupus, Sjögren's syndrome, or other connective tissue diseases in combination with this genotype warrants heightened vigilance. For TT homozygotes the risk is materially elevated and proactive autoantibody screening is appropriate.

The SKIV2L pathway also intersects with innate immune activation triggered by endogenous retroviruses and viral RNA — UV radiation and viral infections (Epstein-Barr virus in particular) are among the most potent known triggers of lupus flares. UV-induced keratinocyte apoptosis releases nuclear antigens that drive the autoantibody cascade; minimizing this exposure is genotype-relevant advice, not generic skin-care guidance.

Interactions

rs419788 (SKIV2L) marks a class III MHC signal that is independent of and additive to the class II signal at HLA-DRB1*0301 (rs2187668 rs7454108 in LD). The rs7574865 (STAT4) T allele acts through an entirely different pathway — amplified interferon-alpha and IL-12 signaling downstream of JAK-STAT — and its effects are also additive with MHC class III risk. Carriers of rs419788-T (SKIV2L risk), rs7574865-T (STAT4 risk), and HLA-DRB1 risk alleles face a substantially elevated composite genetic burden for SLE. The complement-pathway variant rs1270942 (CFB) in the same chromosomal neighbourhood further stratifies risk for immune complex-mediated nephritis; because CFB and SKIV2L are in partial LD, they should be interpreted together rather than as fully independent signals.

The SLC2A9 gene is the single largest genetic determinant of serum uric acid levels in humans, encoding GLUT9¹¹ GLUT9
Glucose Transporter 9, a high-capacity urate transporter in the kidney proximal tubule that reabsorbs urate from the tubular filtrate back into the bloodstream at rates 45–60-fold faster than glucose. What is less widely appreciated is that the SLC2A9 locus contains several genetically independent signals — distinct intronic haplotype blocks, each contributing its own additive effect on renal urate handling. rs4473653 sits at chromosome 4 position 9,969,434 (GRCh38), roughly 8 kb from rs11942223 (another independent signal already in the database) and in a separate haplotype block from both rs11942223 and the coding variant rs3733591 (Arg265His).

The A allele at rs4473653 (the GRCh38 reference allele) tags a haplotype associated with reduced renal urate excretion and elevated steady-state serum uric acid. Its striking rarity in East Asian populations (~11% G-allele frequency, versus ~64% in Africans) mirrors the population pattern seen across SLC2A9 protective variants — where ancestries with the lowest frequency of the protective allele have the highest population burden of gout and hyperuricemia.

The Mechanism

rs4473653 is an intron variant that does not change the GLUT9 protein sequence. Its functional effect is regulatory in nature, consistent with the observation by Wei et al. 2014²² observation by Wei et al. 2014
Wei et al. Abundant local interactions in the 4p16.1 region suggest functional mechanisms underlying SLC2A9 associations. Hum Mol Genet, 2014 that epistatically interacting SNPs at the SLC2A9 locus are enriched at active enhancers in hepatic (HepG2, P = 4.7 × 10⁻⁵) and precursor red blood (K562, P = 5.0 × 10⁻⁶) cells, putatively regulating SLC2A9 transcription. Intronic variants in this region can influence how much GLUT9 protein the kidney produces, thereby modifying the efficiency of urate reabsorption even without changing the transporter's structure.

The G allele is protective: carriers have somewhat higher GLUT9-mediated urate excretion (or lower reabsorption), translating to modestly lower serum uric acid at steady state. The A allele (major allele in most populations) maintains standard or slightly elevated urate reabsorption, raising the urate setpoint. As with all SLC2A9 intronic variants, the effect is substantially larger in women than men³³ substantially larger in women than men
Döring et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008, where estrogen's independent stimulation of renal urate excretion amplifies the phenotypic contrast between genotypes (1.2% variance explained in men vs. up to 6% in women).

The Evidence

Multiple independent signals at the SLC2A9 locus: The SLC2A9 gene region on chromosome 4p16.1 harbours complex genetic architecture. Conditional GWAS analyses have consistently identified multiple statistically independent association signals within the gene's introns, collectively explaining substantially more urate variance than any single lead SNP alone. Wei et al. (2014)⁴⁴ Wei et al. (2014) demonstrated using ARIC and Framingham Heart Study data that a forward-selection model of local interactions at 4p16.1 explained 1.5% more urate variance beyond the single lead SNP, with the interacting variants enriched at functional enhancer elements. The implication is that multiple intronic haplotypes — likely including the block tagged by rs4473653 — independently regulate SLC2A9 expression in metabolically relevant tissues.

Sex-stratified effects across the SLC2A9 locus: The pronounced sex-specific effect at this locus is the most replicated finding in SLC2A9 genetics. Döring et al. (2008)⁵⁵ Döring et al. (2008) showed that intronic SLC2A9 variants explain up to 6% of serum urate variance in women but only 1.2% in men, with each protective minor allele copy reducing uric acid by 0.23–0.36 mg/dL in mixed European cohorts. The mechanism is an interaction between estrogen signalling and renal urate transporters: estrogen independently upregulates fractional excretion of urate, creating a hormonal buffer that makes the genetic signal more visible in women. This buffer is lost at menopause.

Fructose interaction: A fructose challenge study in 76 participants from three ethnic groups demonstrated that SLC2A9 genotype modulates the acute serum urate spike after consuming 64 g of fructose. In European Caucasian participants, carriers of the protective SLC2A9 allele showed a significantly attenuated hyperuricaemic response and higher fractional excretion of uric acid after the fructose load, while this protective effect was not seen in Māori or Pacific Island participants (Dalbeth et al., 2013)⁶⁶ (Dalbeth et al., 2013). This gene-environment interaction confirms that dietary fructose — from sugar-sweetened beverages and concentrated fruit juices — is the highest-leverage dietary modulator for carriers of SLC2A9 risk alleles.

BMI modifies the effect: Brandstätter et al. (2008)⁷⁷ Brandstätter et al. (2008) showed in 1,869 participants that the SLC2A9 protective allele's effect on serum urate (0.30–0.35 mg/dL per copy) was significantly modified by BMI — with substantially larger effects in obese individuals compared to lean participants. This means that AA carriers with high BMI carry a compounded urate burden, while weight reduction and carbohydrate management (especially fructose) are particularly impactful for this genotype.

Practical Actions

The A allele at rs4473653 reflects reduced renal urate clearance through the SLC2A9 transport system. Because this is an independent signal from both rs11942223 and rs3733591, individuals carrying risk alleles at multiple SLC2A9 variants face an additive genetic urate burden that warrants proactive monitoring. For AA homozygotes (the most common genotype globally), the combination of elevated urate setpoint and fructose sensitivity makes sugar-sweetened beverage elimination the single most actionable dietary intervention.

Baseline serum uric acid measurement is warranted for AA carriers, especially women approaching or past menopause when estrogen's buffering effect on renal urate handling disappears. Target below 6 mg/dL (women) or 7 mg/dL (men) — above these thresholds monosodium urate crystal formation can occur in joints, tendons, and the renal pelvis.

Low-fat dairy (associated with inverse gout risk through uricosuric milk proteins), vitamin C supplementation (500 mg/day associated with ~0.5 mg/dL urate reduction), and coffee (2–4 cups/day linked to 20–40% reduced gout incidence) are useful dietary additions that have evidence across SLC2A9 risk genotypes.

Interactions

Independent from rs11942223 and rs3733591: rs4473653 (chr4:9,969,434) and rs11942223 (chr4:9,961,141) are located in separate intronic regions approximately 8 kb apart within SLC2A9. The complex LD structure of the 4p16.1 region means these tag distinct regulatory haplotypes and their effects are additive. Individuals carrying risk alleles at both variants carry compounded genetic urate burden. Similarly, rs3733591 (coding variant Arg265His) operates through a distinct mechanism (protein structure) rather than expression regulation, so all three variants can co-occur independently.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate secretion — a completely separate pathway from the renal reabsorption controlled by SLC2A9. Carrying risk alleles at rs4473653 (renal retention) and ABCG2 Q141K (reduced intestinal efflux) produces an additive elevation that can push serum urate above 7 mg/dL in individuals with otherwise moderate dietary purine intake.

Sex and menopausal status: The SLC2A9 locus shows a substantially larger effect in women (up to 6% of urate variance) than men (1.2%), driven by estrogen interaction with renal urate transporters. Women with the AA genotype at rs4473653 who are peri- or post-menopausal lose this hormonal buffer and represent the highest-risk subgroup — their risk for crossing the hyperuricemia threshold rises at menopause even without any dietary change.

Fructose and BMI: The SLC2A9 protective allele's benefit is attenuated by fructose load (especially from sugar-sweetened beverages) and amplified by higher BMI. AA homozygotes should prioritise both SSB elimination and weight management as the highest-leverage environmental modifiers of their genetically elevated urate setpoint.

The liver's job includes clearing old and damaged glycoproteins from the bloodstream. This housekeeping task is performed by the asialoglycoprotein receptor (ASGR)¹¹ asialoglycoprotein receptor (ASGR)
A heteromeric lectin complex on hepatocyte surfaces that binds and internalizes glycoproteins bearing exposed galactose or N-acetylgalactosamine residues — also called the Ashwell-Morell receptor after its discoverers. One of its subunits, encoded by ASGR1 on chromosome 17, turns out to be a key modulator of plasma cholesterol — and a natural human experiment involving both rare loss-of-function mutations and the common variant rs55714927 has revealed why inhibiting this receptor might be one of the next frontiers in lipid-lowering therapy.

rs55714927 is a synonymous coding variant (Lys89Lys, c.267G>A on the coding strand) that acts as a splicing and expression quantitative trait locus (sQTL/eQTL) for ASGR1. Despite not changing the amino acid sequence, it alters ASGR1 mRNA processing, reducing functional receptor output. Carriers of the A allele show lower LDL and non-HDL cholesterol at levels that reach genome-wide significance in large GWAS datasets.

The Mechanism

ASGR1 sits at the top of an unexpected cholesterol-regulatory cascade. When the receptor functions normally, it binds asialoglycoproteins and delivers them to lysosomes for degradation. The resulting flood of amino acids into the lysosomal lumen activates mTORC1²² mTORC1
the mechanistic target of rapamycin complex 1, a central nutrient-sensing kinase that, among many roles, suppresses AMPK — the cellular energy sensor. Active mTORC1 keeps AMPK suppressed; suppressed AMPK fails to stabilize LXRα, the master transcription factor for reverse cholesterol transport. The net result: less cholesterol pumped out to bile via ABCA1, ABCG5, and ABCG8.

Reduce ASGR1 activity — as the A allele at rs55714927 does — and the chain runs in reverse: reduced lysosomal amino-acid flux → mTORC1 inhibition → AMPK activation → LXRα stabilization → upregulation of ABCA1/ABCG5/G8 → more cholesterol excreted to bile and stool. Simultaneously, AMPK suppresses SREBP1, reducing de novo lipogenesis. ASGR1 also acts as a PCSK9-independent ligand for the hepatic LDL receptor³³ PCSK9-independent ligand for the hepatic LDL receptor
ASGR1 interacts with LDLR on the hepatocyte surface; when ASGR1 levels fall, LDLR expression increases, accelerating LDL clearance by a second mechanism. The combined result — more cholesterol exported out, less produced, and more LDL cleared — yields a meaningful reduction in plasma non-HDL and LDL cholesterol.

The Evidence

The mechanism was established mechanistically by Wang et al. in Nature 2022⁴⁴ Wang et al. in Nature 2022
PMID 35922515 — anti-ASGR1 neutralizing antibodies in mice and cells activated the full AMPK→LXRα→ABCA1/ABCG5/G8 axis and synergized with atorvastatin and ezetimibe to produce greater LDL-C lowering than either drug alone.

The human genetic evidence for rs55714927 as a cholesterol-protective locus comes from several converging sources. Sanna et al., Atherosclerosis 2020 (PMID 32679274)⁵⁵ Sanna et al., Atherosclerosis 2020 (PMID 32679274)
Studied three common ASGR1 locus variants (including rs55714927) in UK Biobank, confirming genome-wide significant LDL-C association and testing for CAD and myocardial infarction outcomes demonstrated that the ASGR1 genetic risk score confers a 23% relative risk reduction for CAD per 10 mg/dL LDL-C reduction (OR 0.77, 95% CI 0.62–0.96). Crucially, this risk reduction was proportionally equivalent to that observed for genetic instruments of HMGCR (statins), NPC1L1 (ezetimibe), PCSK9, and LDLR — evidence that the CAD protection is entirely explained by LDL lowering, with no pleiotropic bonus or penalty.

A drug-target Mendelian randomization study BMC Medicine 2023 (PMID 37400795)⁶⁶ BMC Medicine 2023 (PMID 37400795)
Used rs55714927 and rs150688657 as independent genetic instruments to mimic ASGR1 inhibition across 1,951 health-related phenotypes in UK Biobank found that genetically mimicked ASGR1 inhibition was associated with lower apoB and triglycerides — effects stronger than for statin or ezetimibe genetic instruments — along with a 3.31-year gain in lifespan per standard deviation reduction in LDL-C (95% CI 1.01–5.62). The PheWAS also detected mildly elevated liver enzymes (alkaline phosphatase, GGT), increased IGF-1, CRP, and erythrocyte traits, and reduced albumin and calcium — effects specific to ASGR1 inhibition and not observed with statins.

Animal validation came from ASGR1-deficient pigs (Murata et al. eLife 2021, PMID 34762653)⁷⁷ ASGR1-deficient pigs (Murata et al. eLife 2021, PMID 34762653)
First large-animal model of ASGR1 loss — pigs showed significantly reduced serum LDL-C, reduced atherosclerotic plaque area, and increased hepatic LDLR expression at baseline, which faithfully reproduced the human genetic phenotype in a near-human metabolic model.

Practical Actions

For A-allele carriers at rs55714927, the common-variant effect on LDL-C is modest — roughly 2–5 mg/dL per allele, substantially smaller than the rare del12 loss-of-function (~15 mg/dL). However, because the A allele is present in about 15% of the population, this SNP contributes meaningfully to population-level variation in LDL-C through its additive nature.

The key action point is lipid monitoring: carriers should confirm that the expected non-HDL-C advantage is reflected in measured values. If it is not — particularly in AA homozygotes — other genetic or lifestyle factors may be counteracting it. The effect does not eliminate the need for cardiovascular risk assessment; it modestly improves the starting position.

Interactions

rs55714927 is one of two common GWAS instruments at the ASGR1 locus (the other being rs150688657); both are used together in Mendelian randomization studies to mimic ASGR1 inhibition. The rare variant rs186021206 tags the ASGR1 del12 loss-of-function deletion (r²=0.86) and confers a much larger non-HDL-C reduction (~13–15 mg/dL) — if both rs55714927 and rs186021206 are considered, they represent independent mechanisms at the same gene. In terms of drug interactions, cell and animal data show that ASGR1 inhibition and statin therapy are mechanistically complementary (ASGR1: increases cholesterol excretion; statins: decrease synthesis and increase LDLR recycling), suggesting additive rather than redundant benefits for people already on lipid-lowering therapy.

Every blood clot is a scaffold of cross-linked fibrin, and the enzyme that builds that scaffold is Factor XIII-A (F13A1)¹¹ Factor XIII-A (F13A1)
a plasma transglutaminase activated by thrombin that cross-links fibrin chains, locks in alpha-2-plasmin inhibitor, and makes clots mechanically resistant to dissolution. The Val34Leu variant sits just three amino acids upstream of Factor XIII's thrombin cleavage site — close enough that the single valine-to-leucine swap fundamentally changes how fast the enzyme activates and what kind of clot it builds. Carriers of the Leu34 allele produce fibrin clots that are finer, more porous, and more accessible to fibrinolytic enzymes. The net result is moderate protection against venous thromboembolism and myocardial infarction, particularly in the setting of elevated fibrinogen.

The Mechanism

Factor XIII circulates in plasma as an inactive tetramer (two catalytic A subunits + two carrier B subunits). Thrombin cleaves the activation peptide from each A subunit, exposing the catalytic core. The Val34Leu polymorphism lies at position 34 of the A subunit — only three residues from the thrombin cleavage site at Arg37²² thrombin cleavage site at Arg37
thrombin cuts between Arg37 and Gly38 to activate Factor XIII.

This proximity is decisive. Biochemical studies show that Leu34 allele carriers have a significantly higher maximum rate of FXIII activation by thrombin³³ higher maximum rate of FXIII activation by thrombin
Wartiovaara et al., Thromb Haemost 2000 — the enzyme switches on faster after thrombin arrives. Earlier activation reshapes the fibrin architecture: FXIII that is active sooner cross-links fibrin before the growing polymer has fully polymerized, producing thinner fibers and a more open, permeable mesh. This porous clot structure is more accessible to plasmin, the fibrin-dissolving enzyme, making Leu34 clots easier to lyse.

A 2020 whole-blood clot study (86 donors)⁴⁴ 2020 whole-blood clot study (86 donors)
Kattula et al., J Thromb Haemost 2020 directly demonstrated that this effect is fibrinogen-concentration dependent: when fibrinogen is elevated, Val34 clots grow denser, but Leu34 homozygous clots do not show the same density increase. Since elevated fibrinogen is itself a thrombotic risk factor, the Leu34 allele specifically neutralizes one mechanism by which high fibrinogen promotes clotting.

The Evidence

The strongest evidence for protection against venous thromboembolism (VTE) comes from a meta-analysis of 12 studies (3,165 VTE cases, 4,909 controls)⁵⁵ meta-analysis of 12 studies (3,165 VTE cases, 4,909 controls)
Wells et al., Am J Epidemiol 2006. Leu34 homozygotes had an odds ratio of 0.63 (95% CI 0.46–0.86) for VTE — a 37% reduction in odds. Heterozygotes showed a smaller but still statistically significant protective effect (OR 0.89, 95% CI 0.80–0.99). The authors concluded that Val34Leu has a "small but significant" protective effect, though not large enough on its own to warrant clinical genotyping for VTE risk stratification.

The Leiden Thrombophilia Study⁶⁶ Leiden Thrombophilia Study
Van Hylckama Vlieg et al., Br J Haematol 2002 found that the protective effect in heterozygotes was modest (OR 0.9) but that Leu34 carriers had substantially elevated FXIII activity (158 vs. 95 units in Val/Val carriers), and protection was largely restricted to men.

For arterial disease, a Turkish case-control study found the Leu allele frequency was 7.69% in early MI patients vs. 19.23% in controls (p=0.0001)⁷⁷ Leu allele frequency was 7.69% in early MI patients vs. 19.23% in controls (p=0.0001)
Hancer et al., Circ J 2006, with the protective effect even stronger in patients under 50. A pharmacogenomics study by Undas et al. in Circulation 2003⁸⁸ Undas et al. in Circulation 2003 showed that low-dose aspirin (75 mg/day) selectively amplified FXIII activation rate in Leu34 carriers — raising the possibility that Leu34 carriers gain more cardioprotection from prophylactic aspirin than Val34 homozygotes.

The picture is not uniformly protective. In patients with atrial fibrillation, the Leu34 allele was independently associated with elevated IL-6 and tissue factor levels⁹⁹ atrial fibrillation, the Leu34 allele was independently associated with elevated IL-6 and tissue factor levels
Marín et al., J Mol Cell Cardiol 2004, suggesting it may modulate the prothrombotic-inflammatory state in this condition. One study in coronary artery disease patients on dual antiplatelet therapy found Leu34 homozygotes had shorter clot formation time on thromboelastography and higher rates of recurrent MI, though this finding requires replication.

Practical Actions

For Leu34 carriers, the main implication is awareness of a moderately favorable fibrinolytic profile. The variant does not eliminate thrombotic risk — it shifts the clot formation-dissolution balance slightly toward easier lysis. This is most relevant in the context of elevated fibrinogen (common with chronic inflammation, smoking, obesity, or metabolic syndrome): where a Val/Val individual's clots would grow denser, Leu34 clots remain more permeable.

Elevated fibrinogen reduces the protective effect of the Leu34 allele. Monitoring fibrinogen levels is clinically meaningful for Leu34 homozygotes because their protection depends on fibrinogen being in the normal range.

Carriers with established cardiovascular disease taking low-dose aspirin may derive disproportionate benefit from aspirin's interaction with the Leu34-enhanced FXIII activation rate — this is a genotype-aspirin interaction, not a reason to start aspirin de novo.

Interactions

The Val34Leu effect on VTE is modified by fibrinogen levels — protective at normal fibrinogen, attenuated at elevated concentrations. Fibrinogen is encoded by three genes (FGA, FGB, FGG), and variants in beta-fibrinogen (rs1800787, rs1800790) influence fibrinogen levels and clot structure independently. The combination of Val34Leu with beta-fibrinogen variants affecting fibrinogen concentration or polymerization may have compounding effects on clot architecture not captured by either variant alone.

Factor V Leiden (rs6025) and prothrombin G20210A (rs1799963) are the major inherited thrombophilia alleles. In carriers of Factor V Leiden, the Leu34 allele may partially offset the procoagulant effect, though the interaction is not large enough to eliminate the clinical significance of Factor V Leiden status.

Brown adipose tissue (BAT) is one of the body's most metabolically active organs. Unlike white fat, which stores energy, brown fat burns calories to generate heat — a process called non-shivering thermogenesis¹¹ non-shivering thermogenesis
The production of body heat through mitochondrial uncoupling in brown adipose tissue, activated by cold exposure and sympathetic nervous stimulation. The master effector of this process is uncoupling protein 1 (UCP1)²² uncoupling protein 1 (UCP1)
A mitochondrial inner-membrane protein that allows protons to leak across the membrane without driving ATP synthesis, dissipating energy as heat, encoded exclusively in brown and beige adipocytes.

The rs6536991 variant sits in an intron of the UCP1 gene, 417 nucleotides upstream of exon 8 (c.810-417A>G in coding notation). UCP1 is transcribed from the minus strand of chromosome 4; the allele described as "A" in coding-strand notation corresponds to T on the plus strand reported by genome sequencing files.

The Mechanism

As an intronic variant, rs6536991 does not alter the UCP1 protein sequence. Instead, intronic variants in UCP1 can affect pre-mRNA splicing efficiency, the binding of regulatory proteins to intronic enhancers, or chromatin accessibility at this genomic region. The UCP1 gene contains complex cis-regulatory elements in both promoter and intronic regions that control its highly tissue-specific expression in brown adipose tissue.

The C allele (minor allele in most populations) appears to confer a modest protective effect on obesity risk, most likely by modestly improving UCP1 expression or splicing efficiency — though the precise molecular mechanism has not been established in functional studies. The variant may be in linkage disequilibrium³³ linkage disequilibrium
When two variants are inherited together more often than expected by chance, making one a proxy for the other's effects with nearby functional variants that affect UCP1 regulation.

The Evidence

The most direct evidence comes from a study by Pascual-Gamarra et al. (2019)⁴⁴ study by Pascual-Gamarra et al. (2019)
Pascual-Gamarra JM et al. Association between UCP1, UCP2, and UCP3 gene polymorphisms with markers of adiposity in European adolescents: The HELENA study. Pediatr Obes, 2019 in 1,057 European adolescents aged 12-18. Carriers of the C allele (TC and CC genotypes combined) had significantly lower odds of being overweight compared to TT homozygotes (OR 0.72, 95% CI 0.53-0.98, p=0.034). The effect held after adjusting for physical activity, diet, and other covariates.

An earlier study by Ramos et al. (2012)⁵⁵ Ramos et al. (2012)
Ramos AV et al. The contribution of FTO and UCP-1 SNPs to extreme obesity, diabetes and cardiovascular risk in Brazilian individuals. BMC Med Genet, 2012 in 239 Brazilian subjects (126 morbidly obese vs. 113 normal-weight controls) found rs6536991 significantly associated with BMI (p<0.0001), with an allele dose-dependent pattern — suggesting each additional T allele is associated with a stepwise increase in BMI.

The evidence base for rs6536991 specifically is still limited (three published studies; no functional mechanistic data confirming UCP1 expression effects in human tissue). The effect size is modest and the signal is considered emerging rather than established. Results should be interpreted alongside better-validated UCP1 variants such as rs1800592 (the -3826A>G promoter polymorphism) that has direct functional evidence of reduced UCP1 transcription.

Practical Actions

Brown adipose tissue activity can be increased through several well-documented strategies regardless of genotype, but these strategies are particularly relevant for individuals who carry the TT genotype and may have less efficient BAT function. Brief cold exposure (cool showers, outdoor activity in cool weather) is the most potent physiological stimulus for BAT activation and UCP1 expression. Aerobic exercise also upregulates UCP1 via irisin signaling.

Interactions

rs6536991 should be considered alongside rs1800592 (UCP1 -3826A>G promoter variant). The promoter variant has stronger and better-documented effects on UCP1 expression and brown fat function; individuals who carry risk genotypes at both loci may have compounded reductions in BAT thermogenic capacity. The interaction between these two variants has not been formally studied in compound heterozygosity analyses.

UCP1 function is also modulated by the ADRB3 Trp64Arg variant (rs4994), which affects beta-3 adrenergic signaling — the primary pathway that activates UCP1 in brown fat. Reduced ADRB3 signaling combined with lower UCP1 activity could further impair brown fat thermogenesis.

Exonuclease 1 (EXO1) is a multifunctional nuclease that participates in two of the most consequential DNA maintenance processes in human biology: mismatch repair (MMR)¹¹ mismatch repair (MMR)
the proofreading system that corrects base substitution errors after DNA replication, protecting cells from accumulating mutations and meiotic recombination — the process that generates genetic diversity and ensures proper chromosome segregation during egg and sperm formation. The rs72755295 variant is an intronic regulatory SNP that alters how much EXO1 protein the cell produces, with consequences that reach from the ovary to breast tissue.

The Mechanism

rs72755295 sits within an intron of EXO1 on chromosome 1 (GRCh38 position 241,870,961). It does not change the EXO1 protein sequence but instead modifies a regulatory enhancer element. Shi et al. 2022²² Shi et al. 2022
Breast cancer-associated SNP rs72755295 is a cis-regulatory variation for human EXO1. Genetics and Molecular Biology, 2022 demonstrated that the G allele creates a stronger binding site for the transcription factor PAX6, which drives higher enhancer activity at this locus. The result is elevated EXO1 expression in cells carrying the G allele.

In the ovary, this matters because EXO1 is essential for meiotic crossover formation. Gioia et al. 2023³³ Gioia et al. 2023
Exo1 protects DNA nicks from ligation to promote crossover formation during meiosis. PLoS Biology, 2023 showed that EXO1 shields DNA nick sites during meiosis I prophase, preventing them from being prematurely sealed by ligase enzymes and thereby enabling the Mlh1-Mlh3 endonuclease complex to initiate crossovers. Too little EXO1 means crossovers fail; but the relationship between EXO1 dosage and ovarian ageing is more nuanced — the GWAS signal at this locus suggests altered EXO1 activity or expression in granulosa and oocyte cells influences the pace at which the primordial follicle pool is depleted over a woman's lifetime.

The Evidence

The ovarian ageing connection was first established by Stolk et al. 2012⁴⁴ Stolk et al. 2012
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nature Genetics, 44:260–268, a landmark meta-analysis of 22 GWAS in 38,968 European women with replication in 14,435 additional women. EXO1 was among eight DNA repair genes at newly identified loci reaching genome-wide significance (P < 5 × 10⁻⁸). The striking enrichment of DNA-repair genes at menopause-timing loci — including EXO1, HELQ, UIMC1, FANCI, TLK1, POLG, and PRIM1 — points to a central biological principle: accurate DNA maintenance in oocytes is rate-limiting for ovarian reserve longevity⁵⁵ accurate DNA maintenance in oocytes is rate-limiting for ovarian reserve longevity
Oocytes are arrested in meiotic prophase I for decades, during which accumulated DNA damage is a primary driver of follicle apoptosis and reserve depletion.

Ruth et al. 2021⁶⁶ Ruth et al. 2021
Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 596:393–397 extended this work to a much larger multi-ancestry cohort exceeding 200,000 women, confirming the EXO1 locus among genetic determinants of age at natural menopause (ANM). The estimated per-allele effect at the EXO1 locus is approximately 0.32 years (~17 weeks) later ANM per G allele — meaning carriers of the G allele have, on average, a slightly later menopause. However, because the G allele is rare (~2% globally), it is the A/A common genotype that defines the population mean, and understanding this SNP requires recognising that the G allele appears to modulate EXO1 expression in a direction that influences ovarian reserve trajectory.

The breast cancer dimension adds an important clinical layer. The same rs72755295-G allele that alters ovarian biology also increases EXO1 expression in breast tissue. Since EXO1 is overexpressed in breast carcinoma samples, Shi et al. 2022 demonstrated that the SNP functions as a cis-regulatory element explaining part of the breast cancer GWAS signal at chromosome 1q43.

Practical Actions

For women carrying the G allele, the dual EXO1 signal — modified ovarian reserve trajectory and elevated breast cancer risk through EXO1 overexpression — warrants specific monitoring targeted to each pathway. Ovarian reserve monitoring via AMH measurement provides the most direct readout of reserve trajectory. Breast awareness and adherence to recommended screening schedules is warranted, and women with a family history of breast cancer should discuss this genetic context with their clinician.

Interactions

EXO1 sits within the DNA-repair cluster of ovarian ageing genes identified in both the Stolk 2012 and Ruth 2021 GWAS. Other genes in this cluster — TLK1 (rs10183486), MCM8 (rs16991615), HELQ (rs1046089), and POLG (rs7759938) — each contribute additive risk through related but distinct repair pathways. Women carrying G alleles at rs72755295 combined with risk alleles at TLK1 or MCM8 may have greater cumulative DNA-repair burden in the ovary, though formal compound analyses of the EXO1 pair with these loci have not been published. Pathway-level enrichment analyses from Ruth 2021 show that the meiotic crossover genes and MMR genes collectively explain a disproportionate fraction of menopause-timing variance.

Every cell in your skin can convert sunlight into vitamin D — but only if it has enough [7-dehydrocholesterol (7-DHC) | A cholesterol precursor concentrated in the stratum basale and stratum spinosum of the epidermis; UVB radiation (290–315 nm) breaks its B-ring open to form previtamin D3] to work with. The problem is that 7-DHC is a shared substrate: the same molecule that becomes vitamin D3 in sunlight can also be converted to cholesterol by the enzyme DHCR7 (7-dehydrocholesterol reductase). These two pathways compete on a molecular level, and the genetic variants near DHCR7 tip the balance.

rs7940244 sits in an intron of NADSYN1 (NAD synthetase 1) on chromosome 11, about 61 kilobases downstream from DHCR7. Despite its address in a different gene, this variant is a strong proxy for the canonical DHCR7 vitamin D locus — it travels on the same haplotype block as rs12785878, the primary GWAS hit for serum 25-hydroxyvitamin D levels at this locus. The T allele of rs7940244 co-segregates with the allele of rs12785878 associated with lower circulating vitamin D, almost certainly because both track a regulatory change that modulates DHCR7 expression or activity.

The Mechanism

DHCR7 catalyzes the [final step in the Kandutsch-Russell cholesterol synthesis pathway | One of two cellular routes to cholesterol; DHCR7 uses NADPH to reduce the C7-8 double bond in 7-DHC, converting it irreversibly to cholesterol on the smooth endoplasmic reticulum membrane] by reducing 7-DHC to cholesterol. Every molecule of 7-DHC that DHCR7 converts to cholesterol is a molecule that cannot become vitamin D3. Variants in this region that increase DHCR7 activity or expression therefore lower the skin's capacity for UV-driven vitamin D synthesis, even under identical sun exposure.

The rs7940244 T allele is not itself a coding change — it does not alter any amino acid in NADSYN1. It is a tag SNP for a nearby regulatory haplotype that influences DHCR7 transcription. The precise functional mechanism remains to be defined by eQTL or reporter studies, but the epidemiological signal is clear and has been replicated across populations totaling hundreds of thousands of individuals.

The DHCR7 protein is also subject to a [cholesterol-mediated feedback loop | When cellular cholesterol rises, cholesterol directly accelerates DHCR7 proteasomal degradation, which reduces its activity and allows 7-DHC to accumulate — favoring vitamin D synthesis] that normally balances vitamin D and cholesterol production. Variants that constitutively elevate DHCR7 activity blunt this feedback response.

The Evidence

The DHCR7/NADSYN1 locus is one of the most robustly replicated genetic determinants of circulating vitamin D. The 2010 Lancet GWAS¹¹ 2010 Lancet GWAS
Wang TJ et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010 in 33,996 Europeans identified this locus at P = 2.1×10⁻²⁷. In the Framingham Heart Study subcohort, mean 25(OH)D differed by approximately 8 nmol/L between the low-risk and high-risk homozygous genotypes. Each additional risk allele increased odds of vitamin D insufficiency (below 75 nmol/L) by approximately 21%.

A concurrent GWAS by Ahn et al.²² GWAS by Ahn et al.
Ahn J et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet, 2010 independently confirmed the locus at P = 3.4×10⁻⁹ in 6,722 individuals. More recently, a UK Biobank GWAS in 401,460 participants³³ UK Biobank GWAS in 401,460 participants
Manousaki D et al. Am J Hum Genet, 2020 identified 69 vitamin D loci including DHCR7, and a parallel study of 417,580 Europeans⁴⁴ study of 417,580 Europeans
Revez JA et al. Nat Commun, 2020 identified 143 loci with DHCR7 remaining one of the strongest signals.

The rs7940244 T allele is notably rare in Europeans (~22%) but common in African (~48%) and South Asian populations (~67%), a pattern consistent with a positive selection signal in ancient Europeans⁵⁵ positive selection signal in ancient Europeans
Mathieson I et al. Genome-wide patterns of selection in 230 ancient Eurasians. Nature, 2015 and with the evolutionary hypothesis that, as humans migrated north from equatorial Africa into low-UV environments, variants that preserved 7-DHC for vitamin D synthesis (rather than diverting it to cholesterol) conferred a survival advantage against rickets and immune dysfunction.

Practical Implications

The per-allele effect at the DHCR7/NADSYN1 locus on vitamin D levels is modest — approximately 2–4 nmol/L (about 1 ng/mL) per risk allele — but the biological message is actionable: T allele carriers have a genetic tendency to produce less vitamin D3 from a given amount of sun exposure. This tendency compounds with the environmental risk factors that dominate overall vitamin D status: high latitude, winter season, indoor lifestyle, darker skin, and obesity. For T allele carriers, monitoring vitamin D levels and adjusting supplementation accordingly is more important than for those without this variant.

Critically, this variant affects only the skin synthesis pathway. It does not impair absorption of dietary or supplemental vitamin D. Supplementing with cholecalciferol (D3) or spending more time in direct midday sun are both effective countermeasures.

Interactions

rs7940244 is in strong LD with rs12785878 (r² = 0.703, D' = 0.987 in Europeans), meaning it captures much of the same biological signal. If both rs7940244 and rs12785878 are present in a genome report, they should not be interpreted as independent effects — they reflect the same underlying haplotype.

The three other major vitamin D pathway loci interact with this locus in determining overall vitamin D status: CYP2R1 (rs10741657) encodes the liver 25-hydroxylase that converts vitamin D3 to 25(OH)D; GC (rs2282679) encodes the vitamin D binding protein that transports 25(OH)D in the blood; CYP24A1 (rs6013897) encodes the enzyme that degrades active vitamin D. A combined genetic risk score across these four loci increases odds of insufficiency by up to 2.47-fold compared to the most favorable genotype.

Tucked into the intergenic region of chromosome 14q13.3, rs944289 was one of the first common variants identified as a thyroid cancer susceptibility locus. Discovered in a landmark Icelandic GWAS¹¹ landmark Icelandic GWAS
Gudmundsson et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nature Genetics 2009 alongside rs965513 on chromosome 9, this variant does not sit within a protein-coding gene. Instead, it controls a molecular switch: the expression of PTCSC3²² PTCSC3
Papillary Thyroid Carcinoma Susceptibility Candidate 3, a long noncoding RNA with tumor suppressor properties that is expressed exclusively in thyroid tissue, a long noncoding RNA gene with tumor suppressor activity that is expressed exclusively in the thyroid gland.

The Mechanism

The rs944289 variant sits within a binding site for C/EBP transcription factors³³ binding site for C/EBP transcription factors
CCAAT/enhancer binding proteins alpha and beta, which activate the PTCSC3 promoter. The protective C allele preserves this binding site, allowing C/EBPalpha and C/EBPbeta to activate the PTCSC3 promoter. The risk T allele disrupts this binding site, reducing transcription factor affinity and lowering PTCSC3 expression.

PTCSC3 functions as a tumor suppressor⁴⁴ PTCSC3 functions as a tumor suppressor
Restoration of PTCSC3 expression in PTC cell lines inhibited cell growth and affected genes involved in DNA replication, cellular movement, and cell death in thyroid tissue. When PTCSC3 is experimentally restored in papillary thyroid carcinoma cell lines, it inhibits cell growth and alters the expression of genes involved in DNA replication, recombination, cellular movement, tumor morphology, and cell death. In thyroid tumor tissue from 46 PTC patients, PTCSC3 was strongly downregulated compared to normal thyroid, and TT homozygotes showed the most severe suppression (P=0.004 vs CT heterozygotes).

The PTCSC3 gene is located 3.2 kb downstream of rs944289 and is strictly thyroid-specific in expression⁵⁵ strictly thyroid-specific in expression
Unlike most lncRNAs with broader tissue expression, PTCSC3 transcripts are detected only in thyroid tissue, explaining why this variant specifically affects thyroid cancer risk rather than cancer risk broadly.

The Evidence

The discovery GWAS by Gudmundsson et al.⁶⁶ discovery GWAS by Gudmundsson et al.
Gudmundsson et al. Nature Genetics 2009, 192 Icelandic cases, 37,196 controls with European replication found rs944289 associated with thyroid cancer at an odds ratio of 1.37 per T allele (P=2.0x10^-9). Critically, individuals homozygous for both rs944289-TT and rs965513-AA had a 5.7-fold greater risk of thyroid cancer compared to non-carriers at either locus, with approximately 3.7% of Europeans carrying this double-homozygous genotype.

A meta-analysis of 15 studies⁷⁷ meta-analysis of 15 studies
Chen & Zhang. BMC Medical Genetics 2018 confirmed the association with differentiated thyroid cancer (OR 1.08, 95% CI 1.035-1.131). A separate meta-analysis of 8 case-control studies with 51,120 subjects⁸⁸ separate meta-analysis of 8 case-control studies with 51,120 subjects
Associations between rs965513/rs944289 and papillary thyroid carcinoma risk. Endocrine 2014 found a per-allele OR of 1.29 (95% CI 1.23-1.37) for papillary thyroid carcinoma, with stronger effects in Caucasian populations.

A Japanese population study⁹⁹ Japanese population study
Rogounovitch et al. Thyroid 2015, 535 PTC cases, 959 follicular adenoma cases, 2,766 controls confirmed the association extends to both malignant thyroid tumors (PTC: OR 1.23, P=0.003) and benign thyroid tumors (follicular adenoma: OR 1.18, P=0.002), suggesting the variant acts on early thyroid tumorigenesis rather than malignant transformation specifically.

The T allele frequency varies substantially across populations: approximately 59% in Europeans, 50% in South Asians, 45% in East Asians, 39% in Latinos, and only 21% in Africans. This population stratification partly mirrors global thyroid cancer incidence patterns, though environmental factors like iodine intake and radiation exposure also contribute.

Practical Implications

The rs944289 T allele confers a modest but well-replicated increase in thyroid cancer risk. Because papillary thyroid cancer is relatively uncommon (annual incidence approximately 14 per 100,000), even a 1.37-fold relative risk increase translates to a small absolute risk change for most carriers. However, for individuals with additional risk factors — family history of thyroid cancer, prior radiation exposure, or known thyroid nodules — this genotype provides context for surveillance decisions.

The variant also associates with benign thyroid tumors (follicular adenoma), meaning TT carriers may be more likely to develop thyroid nodules that require evaluation even when they turn out to be non-malignant. Adequate selenium and iodine status support thyroid health and may help mitigate risk.

Interactions

The rs944289 locus on 14q13.3 interacts multiplicatively with the rs965513 locus on 9q22.33 for thyroid cancer risk. The Gudmundsson 2009 study demonstrated that carriers homozygous at both loci face a 5.7-fold increased risk. Both loci operate through distinct regulatory mechanisms — rs944289 through PTCSC3 suppression and rs965513 through PTCSC2/FOXE1 downregulation — but converge on thyroid cell differentiation and tumor suppression pathways. This makes the combination of both risk genotypes substantially more concerning than either alone.